ClinicalTrials.gg
CompletedNCT04927065Updated Feb 28, 2025Results posted

A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants

A Phase 2/3 interventional study of mRNA-1273.211 and mRNA-1273 in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 23 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-28.

Primary conditionCOVID-19Registry: Coronavirus InfectionsReclassifiedWhy we changed it
Registry
Coronavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's title name COVID-19, a narrower term within Coronavirus Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
5,161
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 — 2 open to participants now, 5 under way, 1 of them phase 3. 2019-nCoV Vaccine mRNA-1273 · COVID-19.

Enrollment
5th of 36
5,161 · median 499
Started
2021
with 20 others
Phase 2/3
4 of 36
none open now
Registered
19th of 36
by date
Lead sponsor
11 of 36
ModernaTX, Inc.

Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, this one is the 5th largest by enrollment, is one of 21 that started in 2021, is one of 4 in phase 2/3, and was the 19th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About 2019-nCoV Vaccine mRNA-1273

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, or all of them as a file.
02

Study summary

This is a study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.211, mRNA-1273, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, mRNA-1273.214, mRNA-1273.222, mRNA-1273.815, and mRNA-1273.231 administered as booster doses.

Read the detailed description

This clinical study will consist of 9 parts: A (1 and 2), B, C, D, E, F, G, H, and J.

Part A.1 will evaluate 2 dose levels of the mRNA-1273.211 vaccine when administered as a single booster dose to adult participants of the mRNA-1273-P301 (COVE [NCT04470427]) study who have previously received 2 doses of mRNA-1273.

Part A.2 will evaluate the immunogenicity, safety, and reactogenicity of the mRNA-1273.214 vaccine candidate when administered as a second booster dose to adult participants of the mRNA-1273-P205 study who have previously received 2 doses of mRNA-1273 as a primary series and a first booster of (50 μg total mRNA content) of the mRNA-1273.211 in Part A.1 of this study.

Part B will evaluate the mRNA-1273 vaccine when administered as a single booster dose to adult participants of the mRNA-1273-P301 (COVE [NCT04470427]) study who have previously received 2 doses of mRNA-1273.

Part C will evaluate 2 dose levels of the mRNA-1273.617.2 vaccine when administered as a single booster dose to adult participants of the mRNA-1273-P301 (COVE [NCT04470427]) study who have previously received 2 doses of mRNA-1273.

Part D will evaluate 2 dose levels of the mRNA-1273.213 vaccine when administered as a single booster dose to adult participants of the mRNA-1273-P301 (COVE [NCT04470427]) study who have previously received 2 doses of mRNA-1273.

Part E will be enrolled at a single clinical study site. Part E will evaluate the mRNA-1273.213 vaccine when administered as a single booster dose to adult participants who have previously received 2 doses of any SARS-CoV-2 mRNA authorized vaccine, including mRNA-1273.

Part F will consist of 2 cohorts: Cohort 1 will consist of adults who have previously received 2 doses of mRNA-1273 as primary series. Cohort 1 will evaluate the mRNA-1273.529 vaccine as a single booster dose. Cohort 2 will consist of adults who have previously received 2 doses of mRNA-1273 as a primary series and a single booster dose of mRNA-1273 in study mRNA-1273-P301 (COVE [NCT04470427]) or under the emergency use authorization (EUA). Cohort 2 will evaluate the mRNA-1273.529 and mRNA-1273 vaccines as a single booster dose.

Part G will evaluate the mRNA1273.214 vaccine candidate when administered as a second booster dose to adults who have previously received 2 doses of mRNA-1273 as a primary series and a single booster dose of mRNA-1273.

Part H will evaluate the immunogenicity, safety, and reactogenicity of the mRNA- 1273.222 vaccine candidate when administered as a second booster dose to adults who have previously received 2 doses of mRNA-1273 as a primary series and a single booster dose of mRNA-1273.

Part J will evaluate mRNA-1273.815 and mRNA-1273.231 when administered as a booster dose to adults who previously received a primary series of mRNA vaccine, a first booster dose of a monovalent mRNA vaccine, and a second booster dose of a bivalent mRNA vaccine against SARS-COV-2.

03

Conditions studied

  • SARS-CoV-2

Browse trials for

Keywords

  • mRNA-1273
  • mRNA-1273 vaccine
  • mRNA-1273.211
  • mRNA-1273.617.2
  • mRNA-1273.213
  • mRNA-1273.529
  • mRNA-1273.214
  • mRNA-1273.815
  • mRNA-1273.231
  • SARS-CoV-2
  • SARS-CoV-2 Vaccine
  • Coronavirus
  • Virus Diseases
  • Messenger RNA
  • COVID 19
  • COVID 19 Vaccine
  • Moderna
04

In context

COVID-19 Reclassified

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

This study's enrollment of 5,161 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.

Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • For female participants of : negative pregnancy test, adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreement to continue adequate contraception or abstinence through 3 months following the vaccination, and not currently breastfeeding.
  • Participants must have been either previously enrolled in the mRNA-1273-P301 (COVE) study, must have received 2 doses of mRNA-1273 in that study, with their second dose at least 6 months prior to enrollment in this study (mRNA-1273-P205), and must be currently enrolled and compliant in that study (that is, has not withdrawn or discontinued early); or participant must have received 2 doses of mRNA-1273 under the EUA with their second dose at least 6 months prior to enrollment in mRNA-1273-P205; or have received a 2 dose primary series of mRNA-1273 followed by a 50 μg booster dose of mRNA-1273 in the mRNA-1273-P301 (COVE) study or under EUA at least 3 months prior to enrolment in mRNA-1273-P205; and able to provide proof of vaccination status at the time of screening (Day 1); or for enrollment in Part A.2, participant must be currently enrolled and compliant in Part A.1 of the mRNA 1273 P205 study and must have received their first booster dose of mRNA 1273.211 50 μg; or for enrollment in Part J, participant must meet at least 1 of the following criteria: completed enrollment in Part H of the mRNA-1273-P205 study; or received a 2-dose primary series of mRNA-1273 (100 μg) followed by a 50 μg booster dose of mRNA-1273 in the mRNA-1273-P301 (COVE) study or under EUA, followed by a 50 μg booster dose of mRNA-1273.222 under EUA at least 3 months prior to enrollment in Part J of mRNA-1273-P205; or previously received a 2-dose primary series of mRNA vaccine against SARS-CoV-2 followed by a booster dose of a monovalent mRNA vaccine, followed by a second booster dose of a bivalent mRNA vaccine. Participants in Part J must also provide proof of vaccination status at the time of screening (Day 0 or Day 1).

Key Exclusion Criteria:

  • Significant exposure to someone with SARS-CoV-2 infection or COVID-19 in the past 14 days, as defined by the US Centers for Disease Control and Prevention (CDC) as a close contact of someone who has had COVID-19.
  • Known history of SARS-CoV-2 infection within 3 months prior to enrollment.
  • Is acutely ill or febrile (temperature ≥38.0°Celsius/[100.4°Fahrenheit]) less than 72 hours prior to or at the Screening Visit (Day 0) or Day 1.
  • Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.
  • Has received systemic or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for ≥10 milligrams (mg)/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
  • Known or suspected allergy or history of anaphylaxis, urticaria, or other significant AR to the vaccine or its .
  • Has a documented history of myocarditis or pericarditis within 2 months prior to Screening Visit (Day 0).
  • Has received or plans to receive any licensed vaccine ≤28 days prior to the injection (Day 1) or a licensed vaccine within 28 days before or after they study injection, with the exception of influenza vaccines, which may be given 14 days before or after receipt of a study vaccine.
  • Has received systemic immunoglobulins or blood products within 3 months prior to the Screening Visit (Day 0) or plans for receipt during the study.
  • Has donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit (Day 0) or plans to donate blood products during the study.
  • Is currently experiencing an SAE in Study mRNA-1273-P301 (COVE) at the time of screening for this study.

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

06

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
5,161 participants (actual)

Study arms

  • Experimental
    Part A.1: mRNA-1273.211 50 μg

    Participants will receive 1 intramuscular booster dose of 50 micrograms (μg) of mRNA-1273.211 on Day 1.

    Biological: mRNA-1273.211

  • Experimental
    Part A.1: mRNA-1273.211 100 μg

    Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.211 on Day 1.

    Biological: mRNA-1273.211

  • Experimental
    Part B: mRNA-1273 100 μg

    Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273 on Day 1.

    Biological: mRNA-1273

  • Experimental
    Part C: mRNA-1273.617.2 100 μg

    Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.617.2 on Day 1.

    Biological: mRNA-1273.617.2

  • Experimental
    Part C: mRNA-1273.617.2 50 μg

    Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.617.2 on Day 1.

    Biological: mRNA-1273.617.2

  • Experimental
    Part D: mRNA-1273.213 50 μg

    Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.213 on Day 1.

    Biological: mRNA-1273.213

  • Experimental
    Part D: mRNA-1273.213 100 μg

    Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.213 on Day 1.

    Biological: mRNA-1273.213

  • Experimental
    Part E: mRNA-1273.213 100 μg

    Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.213 on Day 1.

    Biological: mRNA-1273.213

  • Experimental
    Part F Cohort 1: mRNA-1273.529 50 μg

    Participants will receive 1 intramuscular first booster dose of 50 μg of mRNA-1273.529 on Day 1.

    Biological: mRNA-1273.529

  • Experimental
    Part F Cohort 2: mRNA-1273.529 50 μg and mRNA-1273 50 μg

    Participants will receive 1 intramuscular second booster dose of 50 μg of mRNA-1273.529 or mRNA-1273 enrolled sequentially (after receiving a primary series of mRNA-1273 and a single booster dose of mRNA-1273 50 μg) on Day 1.

    Biological: mRNA-1273 · Biological: mRNA-1273.529

  • Experimental
    Part G: mRNA-1273.214 50 μg

    Participants will receive 1 intramuscular second booster dose of mRNA-1273.214 50 μg on Day 1.

    Biological: mRNA-1273.214

  • Experimental
    Part A.2: mRNA-1273.214 50 μg

    Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.214 on Day 1.

    Biological: mRNA-1273.214

  • Experimental
    Part H: mRNA-1273.222 50 μg

    Participants will receive 1 intramuscular second booster dose of 50 μg of mRNA-1273.222 on Day 1.

    Biological: mRNA-1273.222

  • Experimental
    Part J: mRNA-1273.815 or mRNA-1273.231

    Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.815 or 50 ug of mRNA-1273.231 on Day 1.

    Biological: mRNA-1273.815 · Biological: mRNA-1273.231

Interventions

  • BiologicalmRNA-1273.211

    Sterile liquid for injection

  • BiologicalmRNA-1273

    Sterile liquid for injection

  • BiologicalmRNA-1273.617.2

    Sterile liquid for injection

  • BiologicalmRNA-1273.213

    Sterile liquid for injection

  • BiologicalmRNA-1273.529

    Sterile liquid for injection

  • BiologicalmRNA-1273.214

    Sterile liquid for injection

  • BiologicalmRNA-1273.222

    Sterile liquid for injection

  • BiologicalmRNA-1273.815

    Sterile liquid for injection

  • BiologicalmRNA-1273.231

    Sterile liquid for injection

07

What researchers measure

Primary outcomes

  1. Number of Participants With Solicited Local and Systemic ARs

    Solicited ARs (local and systemic) were collected in an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. All solicited ARs considered causally related to injection were graded 0-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicates lower severity, and a higher score indicates greater severity. The Investigator reviewed whether the solicited AR was also to be recorded as an adverse event (AE). A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

    Time frame: 7 days post-vaccination

  2. Number of Participants With Unsolicited AEs

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Number of participants with unsolicited AEs (SAEs and non-serious AEs) up to 28 days post-vaccination are reported in this outcome measure.

    Time frame: Up to 28 days post-vaccination

  3. Number of Participants With SAEs, AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Study or Treatment Discontinuation

    An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that lead to an unscheduled visit to a healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or coronavirus disease 2019 \[COVID-19\] and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). Number of participants with SAEs, AESIs, MAAEs, and AEs leading to discontinuation up to the end of study (EOS) are reported in this outcome measure.

    Time frame: Day 1 to EOS (Day 366 for Parts A.1, B, C, D, E, and F; and Day 181 for Parts A.2, H, and J)

  4. Geometric Mean Titer (GMT) of Serum Pseudovirus Neutralizing Antibody (nAb) ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 29 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)

    GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral severe acute respiratory syndrome coronavirus (SARS-CoV-2) (D614G) at Day 29 is reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5 \* LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 arbitrary units (AU)/milliliter (mL) and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Day 29

  5. GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 181 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)

    GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 181 is reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Day 181

  6. Seroresponse Rate (SRR) (Based on Pre-vaccination Baseline) For Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 29 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)

    Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 29 are reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Day 29

  7. SRR (Based on Pre-booster Baseline) For Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 29 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)

    Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 29 are reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Day 29

  8. SRR (Based on Pre-vaccination Baseline) For Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 181 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)

    Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 181 are reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Day 181

  9. SRR (Based on Pre-booster Baseline) For Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 181 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)

    Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 181 are reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Day 181

  10. GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273

    GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) at Day 29 is reported. Part F (Cohort 2) mRNA-1273.529 50 μg was compared to Part F (Cohort 2) mRNA-1273 50 μg. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.

    Time frame: Day 29

  11. SRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273

    Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 29 are reported. Part F (Cohort 2) mRNA-1273.529 50 μg was compared to Part F (Cohort 2) mRNA-1273 50 μg. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.

    Time frame: Day 29

  12. SRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273

    Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 29 are reported. Part F (Cohort 2) mRNA-1273.529 50 μg was compared to Part F (Cohort 2) mRNA-1273 50 μg. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.

    Time frame: Day 29

  13. GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) and Ancestral SARS-CoV-2 (D614G) at Day 29 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

    GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 29 is reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Day 29

  14. GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) and Ancestral SARS-CoV-2 (D614G) at Day 91 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

    GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 91 is reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Day 91

  15. SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

    Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 29 are reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.

    Time frame: Day 29

  16. SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

    Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 29 are reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.

    Time frame: Day 29

  17. SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 91 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

    Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 91 are reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.

    Time frame: Day 91

  18. SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 91 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

    Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 91 are reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.

    Time frame: Day 91

  19. GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.4/BA.5 Variant and Ancestral SARS-CoV-2 (D614G) at Day 29 - mRNA-1273.222 (Part H) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

    GMT of serum pseudovirus nAb ID50 titers against BA.4/BA.5 and ancestral SARS-CoV-2 (D614G) at Day 29 is reported. mRNA-1273.222 (Part H) was compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Day 29

  20. SRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.4/BA.5 Variant and Ancestral SARS-CoV-2 (D614G) at Day 29 - mRNA-1273.222 (Part H) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

    Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against BA.4/BA.5 and ancestral SARS-CoV-2 (D614G) at Day 29 are reported. mRNA-1273.222 (Part H) was compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Day 29

  21. SRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.4/BA.5 Variant and Ancestral SARS-CoV-2 (D614G) at Day 29 - mRNA-1273.222 (Part H) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

    Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against BA.4/BA.5 and ancestral SARS-CoV-2 (D614G) at Day 29 are reported. mRNA-1273.222 (Part H) was compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Day 29

  22. GMT of Serum Pseudovirus nAb ID50 Titers Against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815

    GMT of serum pseudovirus nAb ID50 titers against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 15 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. Antibody values reported as below the lower limit of detection (LOD) are replaced by 0.5 \* LOD. LOD was 10 AU/mL for ID50 titer against XBB.1.5 and BQ.1.1. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

    Time frame: Day 15

  23. GMT of Serum Pseudovirus nAb ID50 Titers Against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815

    GMT of serum pseudovirus nAb ID50 titers against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 29 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. Antibody values reported as below the LOD are replaced by 0.5 \* LOD. LOD was 10 AU/mL for ID50 titer against XBB.1.5 and BQ.1.1. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

    Time frame: Day 29

  24. Geometric Mean Fold Rise (GMFR) of Serum Pseudovirus nAb ID50 Titers Against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815

    GMFR of serum pseudovirus nAb ID50 titers against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 15 is reported. GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. Antibody values reported as below the LOD are replaced by 0.5 \* LOD. LOD was 10 AU/mL for ID50 titer against XBB.1.5 and BQ.1.1. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

    Time frame: Day 15

  25. GMFR of Serum Pseudovirus nAb ID50 Titers Against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815

    GMFR of serum pseudovirus nAb ID50 titers against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 29 is reported. GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. Antibody values reported as below the LOD are replaced by 0.5 \* LOD. LOD was 10 AU/mL for ID50 titer against XBB.1.5 and BQ.1.1. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5

    Time frame: Day 29

  26. SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815

    Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 15 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

    Time frame: Day 15

  27. SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815

    Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 15 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

    Time frame: Day 15

  28. SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815

    Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 29 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

    Time frame: Day 29

  29. SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815

    Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 29 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

    Time frame: Day 29

Secondary outcomes

  1. GMT of Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273

    GMT of serum pseudovirus nAb ID50 titers against ancestral SARS-CoV-2 (D614G) at Day 29 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Day 29

  2. SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273

    Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) at Day 29 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Day 29

  3. SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273

    Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) at Day 29 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Day 29

  4. SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) on Days 29, 91, 181, and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

    Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) on Days 29, 91, 181, and 366 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Days 29, 91, 181, and 366

  5. SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) on Days 29, 91, 181, and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

    Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) on Days 29, 91, 181, and 366 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Days 29, 91, 181, and 366

  6. GMT of Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 181 - mRNA-1273.222 (Part H)

    GMT of serum pseudovirus nAb ID50 titers against BA.4/BA.5 at Day 181 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

    Time frame: Day 181

  7. GMT of Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 181 - mRNA-1273.222 (Part H) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

    GMT of serum pseudovirus nAb ID50 titers against ancestral SARS-CoV-2 (D614G) at Day 181 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Day 181

  8. SRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 181 - mRNA-1273.222 (Part H)

    Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 181 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

    Time frame: Day 181

  9. SRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 181 - mRNA-1273.222 (Part H) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

    Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) at Day 181 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Day 181

  10. SRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 181 - mRNA-1273.222 (Part H)

    Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 181 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

    Time frame: Day 181

  11. SRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 181 - mRNA-1273.222 (Part H) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

    Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) at Day 181 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Day 181

  12. SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Days 181 and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

    Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Days 181 and 366 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.

    Time frame: Days 181 and 366

  13. SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Days 181 and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

    Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Days 181 and 366 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.

    Time frame: Days 181 and 366

  14. GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) and Ancestral SARS-CoV-2 (D614G) on Days 181 and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

    GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) on Days 181 and 366 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

    Time frame: Days 181 and 366

08

Results

Posted Feb 28, 2025

Participant flow

First Booster
Participant flow — First Booster
MilestonePart A.1: mRNA-1273.211 50 μgPart A.1: mRNA-1273.211 100 μgPart A.2: mRNA-1273.214 50 μgPart B: mRNA-1273 100 μgPart C: mRNA-1273.617.2 50 μgPart C: mRNA-1273.617.2 100 μgPart D: mRNA-1273.213 50 μgPart D: mRNA-1273.213 100 μgPart E: mRNA-1273.213 100 μgPart F (Cohort 1): mRNA-1273.529 50 μgPart F (Cohort 2): mRNA-1273 50 μgPart F (Cohort 2): mRNA-1273.529 50 μgPart G: mRNA-1273.214 50 μgPart H: mRNA-1273.222 50 μgPart J: mRNA-1273.231 50 μgPart J: mRNA-1273.815 50 μg
Started300593030558158632758342133000000
Safety set300593030558158632758342133000000
Solicited safety set298591030357758332758342133000000
Per-protocol immunogenicity sars-cov-2 negative set (ppis-neg)295563024548954725050900000000
Per-protocol immunogenicity set (ppis)299576025753756931454300000000
Completed276545026751553629152438110000000
Not completed244803866503659423000000
Withdrew: Adverse event1000000100000000
Withdrew: Death1001010000000000
Withdrew: Lost to follow-up82001143302823415000000
Withdrew: Physician decision1003110300000000
Withdrew: Protocol violation4403000200000000
Withdrew: Withdrawal by subject823019201562404000000
Withdrew: Other than specified1101232604000000
Second Booster
Participant flow — Second Booster
MilestonePart A.1: mRNA-1273.211 50 μgPart A.1: mRNA-1273.211 100 μgPart A.2: mRNA-1273.214 50 μgPart B: mRNA-1273 100 μgPart C: mRNA-1273.617.2 50 μgPart C: mRNA-1273.617.2 100 μgPart D: mRNA-1273.213 50 μgPart D: mRNA-1273.213 100 μgPart E: mRNA-1273.213 100 μgPart F (Cohort 1): mRNA-1273.529 50 μgPart F (Cohort 2): mRNA-1273 50 μgPart F (Cohort 2): mRNA-1273.529 50 μgPart G: mRNA-1273.214 50 μgPart H: mRNA-1273.222 50 μgPart J: mRNA-1273.231 50 μgPart J: mRNA-1273.815 50 μg
Started00135000000037637543751000
Safety set00135000000037637543751000
Solicited safety set00128000000035037243750700
Ppis-neg0076000000025827333420900
Ppis00126000000036235842849400
Completed00128000000035634540548200
Not completed00700000002030322800
Withdrew: Death0000000000202200
Withdrew: Lost to follow-up00300000001410131600
Withdrew: Physician decision0000000000030100
Withdrew: Withdrawal by subject004000000031613900
Withdrew: Other than specified0000000000114000
Third Booster
Participant flow — Third Booster
MilestonePart A.1: mRNA-1273.211 50 μgPart A.1: mRNA-1273.211 100 μgPart A.2: mRNA-1273.214 50 μgPart B: mRNA-1273 100 μgPart C: mRNA-1273.617.2 50 μgPart C: mRNA-1273.617.2 100 μgPart D: mRNA-1273.213 50 μgPart D: mRNA-1273.213 100 μgPart E: mRNA-1273.213 100 μgPart F (Cohort 1): mRNA-1273.529 50 μgPart F (Cohort 2): mRNA-1273 50 μgPart F (Cohort 2): mRNA-1273.529 50 μgPart G: mRNA-1273.214 50 μgPart H: mRNA-1273.222 50 μgPart J: mRNA-1273.231 50 μgPart J: mRNA-1273.815 50 μg
Started000000000000005050
Safety set000000000000005050
Solicited safety set000000000000005050
Ppis-neg000000000000001116
Ppis000000000000004949
Completed000000000000005048
Not completed0000000000000002
Withdrew: Lost to follow-up0000000000000001
Withdrew: Withdrawal by subject0000000000000001

Outcome measures

PrimaryNumber of Participants With Solicited Local and Systemic ARs

Solicited ARs (local and systemic) were collected in an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. All solicited ARs considered causally related to injection were graded 0-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicates lower severity, and a higher score indicates greater severity. The Investigator reviewed whether the solicited AR was also to be recorded as an adverse event (AE). A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.

Time frame:
7 days post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local and Systemic ARs
ParticipantsPart A.1: mRNA-1273.211 50 μgPart A.1: mRNA-1273.211 100 μgPart A.2: mRNA-1273.214 50 μgPart B: mRNA-1273 100 μgPart C: mRNA-1273.617.2 50 μgPart C: mRNA-1273.617.2 100 μgPart D: mRNA-1273.213 50 μgPart D: mRNA-1273.213 100 μgPart E: mRNA-1273.213 100 μgPart F (Cohort 1): mRNA-1273.529 50 μgPart F (Cohort 2): mRNA-1273 50 μgPart F (Cohort 2): mRNA-1273.529 50 μgPart G: mRNA-1273.214 50 μgPart H: mRNA-1273.222 50 μgPart J: mRNA-1273.231 50 μgPart J: mRNA-1273.815 50 μg
Any270554113290532548307550411133003233804434438
Grade 1140215709526019313421311591842032202192823
Grade 29825027144201248127227254388931251651014
Grade 33288165171107461105112827355961
Grade 40100000000000000
PrimaryNumber of Participants With Unsolicited AEs

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Number of participants with unsolicited AEs (SAEs and non-serious AEs) up to 28 days post-vaccination are reported in this outcome measure.

Time frame:
Up to 28 days post-vaccination
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited AEs
ParticipantsPart A.1: mRNA-1273.211 50 μgPart A.1: mRNA-1273.211 100 μgPart A.2: mRNA-1273.214 50 μgPart B: mRNA-1273 100 μgPart C: mRNA-1273.617.2 50 μgPart C: mRNA-1273.617.2 100 μgPart D: mRNA-1273.213 50 μgPart D: mRNA-1273.213 100 μgPart E: mRNA-1273.213 100 μgPart F (Cohort 1): mRNA-1273.529 50 μgPart F (Cohort 2): mRNA-1273 50 μgPart F (Cohort 2): mRNA-1273.529 50 μgPart G: mRNA-1273.214 50 μgPart H: mRNA-1273.222 50 μgPart J: mRNA-1273.231 50 μgPart J: mRNA-1273.815 50 μg
Number of Participants With Unsolicited AEs6212624541341269113552780828311995
PrimaryNumber of Participants With SAEs, AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Study or Treatment Discontinuation

An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that lead to an unscheduled visit to a healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or coronavirus disease 2019 \[COVID-19\] and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). Number of participants with SAEs, AESIs, MAAEs, and AEs leading to discontinuation up to the end of study (EOS) are reported in this outcome measure.

Time frame:
Day 1 to EOS (Day 366 for Parts A.1, B, C, D, E, and F; and Day 181 for Parts A.2, H, and J)
Reported as:
Count of participants · Participants
Number of Participants With SAEs, AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Study or Treatment Discontinuation
ParticipantsPart A.1: mRNA-1273.211 50 μgPart A.1: mRNA-1273.211 100 μgPart A.2: mRNA-1273.214 50 μgPart B: mRNA-1273 100 μgPart C: mRNA-1273.617.2 50 μgPart C: mRNA-1273.617.2 100 μgPart D: mRNA-1273.213 50 μgPart D: mRNA-1273.213 100 μgPart E: mRNA-1273.213 100 μgPart F (Cohort 1): mRNA-1273.529 50 μgPart F (Cohort 2): mRNA-1273 50 μgPart F (Cohort 2): mRNA-1273.529 50 μgPart G: mRNA-1273.214 50 μgPart H: mRNA-1273.222 50 μgPart J: mRNA-1273.231 50 μgPart J: mRNA-1273.815 50 μg
SAEs6263152712818022016231232
AESIs316114242862522101419912
MAAEs2013885818338041724240134782792712922532724
AEs Leading to Discontinuation1000000100000000
PrimaryGeometric Mean Titer (GMT) of Serum Pseudovirus Neutralizing Antibody (nAb) ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 29 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)

GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral severe acute respiratory syndrome coronavirus (SARS-CoV-2) (D614G) at Day 29 is reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5 \* LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 arbitrary units (AU)/milliliter (mL) and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Day 29
Reported as:
Geometric mean · titer
Geometric Mean Titer (GMT) of Serum Pseudovirus Neutralizing Antibody (nAb) ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 29 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)
titerPart A.2: mRNA-1273.214 50 μgPart A.1: mRNA-1273.211 50 μg
Omicron BA.1 Variant (B.1.1.529) nAb4713.5 (3513.5 to 6323.4)1897.1 (1433.8 to 2510.1)
SARS-CoV-2 (D614G) nAb5642.3 (4531.1 to 7025.9)2861.4 (2396.0 to 3417.1)
Statistical analysis
  • Part A.2: mRNA-1273.214 50 μg vs Part A.1: mRNA-1273.211 50 μg · Geometric mean ratio (gmr): 2.5 · 95% CI 2.0 to 3.0Omicron BA.1 Variant (B.1.1.529) nAB: Part A.2 versus Part A.1
  • Part A.2: mRNA-1273.214 50 μg vs Part A.1: mRNA-1273.211 50 μg · Gmr: 2.0 · 95% CI 1.7 to 2.3SARS-CoV-2 (D614G) nAb: Part A.2 versus Part A.1
PrimaryGMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 181 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)

GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 181 is reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Day 181
Reported as:
Geometric mean · titer
GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 181 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)
titerPart A.2: mRNA-1273.214 50 μgPart A.1: mRNA-1273.211 50 μg
Omicron BA.1 Variant (B.1.1.529) nAb2304.6 (1584.4 to 3352.0)379.3 (281.0 to 512.1)
SARS-CoV-2 (D614G) nAb2945.2 (2259.1 to 3839.7)1121.4 (927.4 to 1356.1)
Statistical analysis
  • Part A.2: mRNA-1273.214 50 μg vs Part A.1: mRNA-1273.211 50 μg · Geometric mean ratio (gmr): 6.3 · 95% CI 4.5 to 8.9Omicron BA.1 Variant (B.1.1.529) nAb: Part A.2 versus Part A.1
  • Part A.2: mRNA-1273.214 50 μg vs Part A.1: mRNA-1273.211 50 μg · Gmr: 2.8 · 95% CI 2.1 to 3.6SARS-CoV-2 (D614G) nAb: Part A.2 versus Part A.1
PrimarySeroresponse Rate (SRR) (Based on Pre-vaccination Baseline) For Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 29 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)

Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 29 are reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Day 29
Reported as:
Number · percentage of participants
Seroresponse Rate (SRR) (Based on Pre-vaccination Baseline) For Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 29 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)
percentage of participantsPart A.2: mRNA-1273.214 50 μgPart A.1: mRNA-1273.211 50 μg
Omicron BA.1 Variant (B.1.1.529) nAb100 (95.3 to 100.0)98.7 (92.9 to 100.0)
SARS-CoV-2 (D614G) nAb100 (95.3 to 100.0)100 (95.3 to 100.0)
Statistical analysis
  • Part A.2: mRNA-1273.214 50 μg vs Part A.1: mRNA-1273.211 50 μg · Percentage difference: 1.3 · 95% CI -3.1 to 5.6Omicron BA.1 Variant (B.1.1.529) nAb: Part A.2 versus Part A.1
  • Part A.2: mRNA-1273.214 50 μg vs Part A.1: mRNA-1273.211 50 μg · Percentage difference: 0SARS-CoV-2 (D614G) nAb: Part A.2 versus Part A.1
PrimarySRR (Based on Pre-booster Baseline) For Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 29 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)

Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 29 are reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Day 29
Reported as:
Number · percentage of participants
SRR (Based on Pre-booster Baseline) For Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 29 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)
percentage of participantsPart A.2: mRNA-1273.214 50 μgPart A.1: mRNA-1273.211 50 μg
Omicron BA.1 Variant (B.1.1.529) nAb97.4 (90.8 to 99.7)98.7 (92.9 to 100.0)
SARS-CoV-2 (D614G) nAb93.4 (85.3 to 97.8)96.1 (88.9 to 99.2)
Statistical analysis
  • Part A.2: mRNA-1273.214 50 μg vs Part A.1: mRNA-1273.211 50 μg · Percentage difference: -1.3 · 95% CI -6.9 to 4.3Omicron variant (B.1.1.529) nAb: Part A.2 versus Part A.1
  • Part A.2: mRNA-1273.214 50 μg vs Part A.1: mRNA-1273.211 50 μg · Percentage difference: -2.6 · 95% CI -9.6 to 4.5SARS-CoV-2 (D614G) nAb: Part A.2 versus Part A.1
PrimarySRR (Based on Pre-vaccination Baseline) For Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 181 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)

Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 181 are reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Day 181
Reported as:
Number · percentage of participants
SRR (Based on Pre-vaccination Baseline) For Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 181 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)
percentage of participantsPart A.2: mRNA-1273.214 50 μgPart A.1: mRNA-1273.211 50 μg
Omicron BA.1 Variant (B.1.1.529) nAb100 (94.9 to 100.0)86.5 (76.5 to 93.3)
SARS-CoV-2 (D614G) nAb100 (94.9 to 100.0)100 (95.1 to 100.0)
Statistical analysis
  • Part A.2: mRNA-1273.214 50 μg vs Part A.1: mRNA-1273.211 50 μg · Percentage difference: 12.9 · 95% CI 4.1 to 21.6Omicron BA.1 variant (B.1.1.529) nAb: Part A.2 versus Part A.1
  • Part A.2: mRNA-1273.214 50 μg vs Part A.1: mRNA-1273.211 50 μg · Percentage difference: 0SARS-CoV-2 (D614G) nAb: Part A.2 versus Part A.1
PrimarySRR (Based on Pre-booster Baseline) For Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 181 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)

Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 181 are reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Day 181
Reported as:
Number · percentage of participants
SRR (Based on Pre-booster Baseline) For Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 181 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)
percentage of participantsPart A.2: mRNA-1273.214 50 μgPart A.1: mRNA-1273.211 50 μg
Omicron BA.1 Variant (B.1.1.529) nAb81.4 (70.3 to 89.7)78.4 (67.3 to 87.1)
SARS-CoV-2 (D614G) nAb71.4 (59.4 to 81.6)79.7 (68.8 to 88.2)
Statistical analysis
  • Part A.2: mRNA-1273.214 50 μg vs Part A.1: mRNA-1273.211 50 μg · Percentage difference: 2.9 · 95% CI -11.4 to 17.1Omicron BA.1 variant (B.1.1.529) nAb: Part A.2 versus Part A.1
  • Part A.2: mRNA-1273.214 50 μg vs Part A.1: mRNA-1273.211 50 μg · Percentage difference: -7.1 · 95% CI -21.6 to 7.3SARS-CoV-2 (D614G) nAb: Part A.2 versus Part A.1
PrimaryGMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273

GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) at Day 29 is reported. Part F (Cohort 2) mRNA-1273.529 50 μg was compared to Part F (Cohort 2) mRNA-1273 50 μg. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.

Time frame:
Day 29
Reported as:
Geometric mean · titer
GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273
titerPart F (Cohort 2): mRNA-1273.529 50 μgPart F (Cohort 2): mRNA-1273 50 μg
GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-12732739.5 (2320.2 to 3234.6)1462.1 (1260.1 to 1696.4)
Statistical analysis
  • Part F (Cohort 2): mRNA-1273.529 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Gmr: 1.777 · 95% CI 1.523 to 2.073Omicron BA.1 Variant (B.1.1.529) nAb - Part F (Cohort 2): mRNA-1273.529 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
PrimarySRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273

Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 29 are reported. Part F (Cohort 2) mRNA-1273.529 50 μg was compared to Part F (Cohort 2) mRNA-1273 50 μg. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.

Time frame:
Day 29
Reported as:
Number · percentage of participants
SRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273
percentage of participantsPart F (Cohort 2): mRNA-1273.529 50 μgPart F (Cohort 2): mRNA-1273 50 μg
SRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-127399.6 (98.0 to 100.0)99.2 (97.2 to 99.9)
Statistical analysis
  • Part F (Cohort 2): mRNA-1273.529 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Percentage difference: 0.6 · 95% CI -1.7 to 3.0Omicron BA.1 Variant (B.1.1.529) nAb - Part F (Cohort 2): mRNA-1273.529 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
PrimarySRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273

Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 29 are reported. Part F (Cohort 2) mRNA-1273.529 50 μg was compared to Part F (Cohort 2) mRNA-1273 50 μg. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.

Time frame:
Day 29
Reported as:
Number · percentage of participants
SRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273
percentage of participantsPart F (Cohort 2): mRNA-1273.529 50 μgPart F (Cohort 2): mRNA-1273 50 μg
SRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-127371.4 (65.7 to 76.7)53.5 (47.2 to 59.7)
Statistical analysis
  • Part F (Cohort 2): mRNA-1273.529 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Percentage difference: 17.9 · 95% CI 9.8 to 26.0Omicron BA.1 Variant (B.1.1.529) nAb - Part F (Cohort 2): mRNA-1273.529 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
PrimaryGMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) and Ancestral SARS-CoV-2 (D614G) at Day 29 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 29 is reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Day 29
Reported as:
Geometric mean · titer
GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) and Ancestral SARS-CoV-2 (D614G) at Day 29 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
titerPart G: mRNA-1273.214 50 μgPart F (Cohort 2): mRNA-1273 50 μg
Omicron BA.1 Variant (B.1.1.529) nAb2370.5 (2068.8 to 2716.1)1462.1 (1260.1 to 1696.4)
SARS-CoV-2 (D614G) nAb5971.6 (5316.7 to 6707.2)5621.4 (5029.2 to 6283.4)
Statistical analysis
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Gmr: 1.744 · 97.5% CI 1.492 to 2.040Omicron BA.1 Variant (B.1.1.529) nAb: Part G: mRNA-1273.214 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Gmr: 1.211 · 97.5% CI 1.074 to 1.366SARS-CoV-2 (D614G) nAb: Part G: mRNA-1273.214 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
PrimaryGMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) and Ancestral SARS-CoV-2 (D614G) at Day 91 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 91 is reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Day 91
Reported as:
Geometric mean · titer
GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) and Ancestral SARS-CoV-2 (D614G) at Day 91 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
titerPart G: mRNA-1273.214 50 μgPart F (Cohort 2): mRNA-1273 50 μg
Omicron BA.1 Variant (B.1.1.529) nAb967.3 (835.0 to 1120.6)624.2 (533.1 to 730.9)
SARS-CoV-2 (D614G) nAb3431.5 (3066.7 to 3839.8)3447.1 (3054.7 to 3889.9)
Statistical analysis
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Gmr: 1.676 · 97.5% CI 1.396 to 2.013Omicron BA.1 Variant (B.1.1.529) nAb: Part G: mRNA-1273.214 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Gmr: 1.105 · 97.5% CI 0.970 to 1.260SARS-CoV-2 (D614G) nAb: Part G: mRNA-1273.214 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
PrimarySRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 29 are reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.

Time frame:
Day 29
Reported as:
Number · percentage of participants
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
percentage of participantsPart G: mRNA-1273.214 50 μgPart F (Cohort 2): mRNA-1273 50 μg
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)100 (98.9 to 100.0)99.2 (97.2 to 99.9)
Statistical analysis
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Percentage difference: 1.5 · 97.5% CI -1.1 to 4.1Omicron BA.1 Variant (B.1.1.529) nAb: Part G: mRNA-1273.214 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
PrimarySRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 29 are reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.

Time frame:
Day 29
Reported as:
Number · percentage of participants
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
percentage of participantsPart G: mRNA-1273.214 50 μgPart F (Cohort 2): mRNA-1273 50 μg
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)75.1 (70.2 to 79.7)53.5 (47.2 to 59.7)
Statistical analysis
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Percentage difference: 21.5 · 97.5% CI 12.8 to 30.2Omicron BA.1 Variant (B.1.1.529) nAb: Part G: mRNA-1273.214 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
PrimarySRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 91 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 91 are reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.

Time frame:
Day 91
Reported as:
Number · percentage of participants
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 91 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
percentage of participantsPart G: mRNA-1273.214 50 μgPart F (Cohort 2): mRNA-1273 50 μg
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 91 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)98.2 (96.1 to 99.3)96.3 (93.0 to 98.3)
Statistical analysis
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Percentage difference: 1.8 · 97.5% CI -1.9 to 5.6Omicron BA.1 Variant (B.1.1.529) nAb: Part G: mRNA-1273.214 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
PrimarySRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 91 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 91 are reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.

Time frame:
Day 91
Reported as:
Number · percentage of participants
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 91 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
percentage of participantsPart G: mRNA-1273.214 50 μgPart F (Cohort 2): mRNA-1273 50 μg
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 91 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)38.6 (33.3 to 44.1)17.7 (13.1 to 23.1)
Statistical analysis
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Percentage difference: 20.6 · 97.5% CI 12.4 to 28.7Omicron BA.1 Variant (B.1.1.529) nAb: Part G: mRNA-1273.214 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
PrimaryGMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.4/BA.5 Variant and Ancestral SARS-CoV-2 (D614G) at Day 29 - mRNA-1273.222 (Part H) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

GMT of serum pseudovirus nAb ID50 titers against BA.4/BA.5 and ancestral SARS-CoV-2 (D614G) at Day 29 is reported. mRNA-1273.222 (Part H) was compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Day 29
Reported as:
Geometric mean · titer
GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.4/BA.5 Variant and Ancestral SARS-CoV-2 (D614G) at Day 29 - mRNA-1273.222 (Part H) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
titerPart H: mRNA-1273.222 50 μgPart F (Cohort 2): mRNA-1273 50 μg
Omicron Variant (BA.4/BA.5)2322.6 (1919.9 to 2809.7)483.0 (423.1 to 551.3)
SARS-CoV-2 (D614G) nAb7328.4 (6390.6 to 8403.8)5621.4 (5029.2 to 6283.4)
Statistical analysis
  • Part H: mRNA-1273.222 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Gmr: 6.412 · 95% CI 5.369 to 7.658Omicron Variant (BA.4/BA.5) nAb: Part H mRNA-1273.222 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
  • Part H: mRNA-1273.222 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Gmr: 1.967 · 95% CI 1.708 to 2.265SARS-CoV-2 (D614G) nAb: Part H mRNA-1273.222 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
PrimarySRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.4/BA.5 Variant and Ancestral SARS-CoV-2 (D614G) at Day 29 - mRNA-1273.222 (Part H) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against BA.4/BA.5 and ancestral SARS-CoV-2 (D614G) at Day 29 are reported. mRNA-1273.222 (Part H) was compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Day 29
Reported as:
Number · percentage of participants
SRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.4/BA.5 Variant and Ancestral SARS-CoV-2 (D614G) at Day 29 - mRNA-1273.222 (Part H) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
percentage of participantsPart H: mRNA-1273.222 50 μgPart F (Cohort 2): mRNA-1273 50 μg
Omicron Variant (BA.4/BA.5)98.1 (95.2 to 99.5)86.3 (81.5 to 90.3)
SARS-CoV-2 (D614G) nAb100 (98.3 to 100.0)100 (98.6 to 100.0)
Statistical analysis
  • Part H: mRNA-1273.222 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Percentage difference: 12.2 · 95% CI 6.9 to 17.4Omicron Variant (BA.4/BA.5) nAb: Part H mRNA-1273.222 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
  • Part H: mRNA-1273.222 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Percentage difference: 0SARS-CoV-2 (D614G) nAb: Part H mRNA-1273.222 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
PrimarySRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.4/BA.5 Variant and Ancestral SARS-CoV-2 (D614G) at Day 29 - mRNA-1273.222 (Part H) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against BA.4/BA.5 and ancestral SARS-CoV-2 (D614G) at Day 29 are reported. mRNA-1273.222 (Part H) was compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Day 29
Reported as:
Number · percentage of participants
SRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.4/BA.5 Variant and Ancestral SARS-CoV-2 (D614G) at Day 29 - mRNA-1273.222 (Part H) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
percentage of participantsPart H: mRNA-1273.222 50 μgPart F (Cohort 2): mRNA-1273 50 μg
Omicron Variant (BA.4/BA.5)91.4 (86.7 to 94.8)37.6 (31.7 to 43.8)
SARS-CoV-2 (D614G) nAb80.9 (74.9 to 86.0)43.0 (36.9 to 49.3)
Statistical analysis
  • Part H: mRNA-1273.222 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Percentage difference: 54.7 · 95% CI 47.5 to 61.8Omicron Variant (BA.4/BA.5) nAb: Part H mRNA-1273.222 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
  • Part H: mRNA-1273.222 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Percentage difference: 37.6 · 95% CI 29.3 to 45.9SARS-CoV-2 (D614G) nAb: Part H mRNA-1273.222 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
PrimaryGMT of Serum Pseudovirus nAb ID50 Titers Against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815

GMT of serum pseudovirus nAb ID50 titers against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 15 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. Antibody values reported as below the lower limit of detection (LOD) are replaced by 0.5 \* LOD. LOD was 10 AU/mL for ID50 titer against XBB.1.5 and BQ.1.1. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

Time frame:
Day 15
Reported as:
Geometric mean · titer
GMT of Serum Pseudovirus nAb ID50 Titers Against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815
titerPart J: mRNA-1273.231 50 μgPart J: mRNA-1273.815 50 μg
SARS-CoV-2 (XBB.1.5) nAb1751.2 (1212.5 to 2529.4)2579.0 (1809.1 to 3676.7)
SARS-CoV-2 (BA.4/BA.5) nAb9600.1 (7392.8 to 12466.4)9673.4 (6965.6 to 13433.8)
SARS-CoV-2 (BQ.1.1) nAb1806.7 (1294.1 to 2522.2)1894.1 (1383.2 to 2593.6)
PrimaryGMT of Serum Pseudovirus nAb ID50 Titers Against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815

GMT of serum pseudovirus nAb ID50 titers against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 29 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. Antibody values reported as below the LOD are replaced by 0.5 \* LOD. LOD was 10 AU/mL for ID50 titer against XBB.1.5 and BQ.1.1. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

Time frame:
Day 29
Reported as:
Geometric mean · titer
GMT of Serum Pseudovirus nAb ID50 Titers Against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815
titerPart J: mRNA-1273.231 50 μgPart J: mRNA-1273.815 50 μg
SARS-CoV-2 (XBB.1.5) nAb1985.5 (1388.7 to 2838.8)2710.6 (1778.3 to 4131.8)
SARS-CoV-2 (BA.4/BA.5) nAb10469.7 (7771.5 to 14104.8)11231.0 (7883.5 to 15999.9)
SARS-CoV-2 (BQ.1.1) nAb1727.4 (1293.0 to 2307.6)1991.1 (1308.6 to 3029.5)
PrimaryGeometric Mean Fold Rise (GMFR) of Serum Pseudovirus nAb ID50 Titers Against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815

GMFR of serum pseudovirus nAb ID50 titers against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 15 is reported. GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. Antibody values reported as below the LOD are replaced by 0.5 \* LOD. LOD was 10 AU/mL for ID50 titer against XBB.1.5 and BQ.1.1. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

Time frame:
Day 15
Reported as:
Geometric mean · ratio
Geometric Mean Fold Rise (GMFR) of Serum Pseudovirus nAb ID50 Titers Against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815
ratioPart J: mRNA-1273.231 50 μgPart J: mRNA-1273.815 50 μg
SARS-CoV-2 (XBB.1.5) nAb11.0 (8.4 to 14.5)16.7 (12.8 to 21.7)
SARS-CoV-2 (BA.4/BA.5) nAb5.0 (3.8 to 6.6)6.3 (4.8 to 8.2)
SARS-CoV-2 (BQ.1.1) nAb5.7 (4.5 to 7.2)5.9 (4.8 to 7.4)
PrimaryGMFR of Serum Pseudovirus nAb ID50 Titers Against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815

GMFR of serum pseudovirus nAb ID50 titers against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 29 is reported. GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. Antibody values reported as below the LOD are replaced by 0.5 \* LOD. LOD was 10 AU/mL for ID50 titer against XBB.1.5 and BQ.1.1. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5

Time frame:
Day 29
Reported as:
Geometric mean · ratio
GMFR of Serum Pseudovirus nAb ID50 Titers Against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815
ratioPart J: mRNA-1273.231 50 μgPart J: mRNA-1273.815 50 μg
SARS-CoV-2 (XBB.1.5) nAb12.5 (9.6 to 16.3)17.5 (13.0 to 23.6)
SARS-CoV-2 (BA.4/BA.5) nAb5.5 (4.2 to 7.1)7.3 (5.4 to 9.9)
SARS-CoV-2 (BQ.1.1) nAb5.4 (4.3 to 7.0)6.2 (4.6 to 8.4)
PrimarySRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815

Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 15 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

Time frame:
Day 15
Reported as:
Number · percentage of participants
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815
percentage of participantsPart J: mRNA-1273.231 50 μgPart J: mRNA-1273.815 50 μg
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815100 (88.8 to 100.0)100 (90.5 to 100.0)
PrimarySRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815

Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 15 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

Time frame:
Day 15
Reported as:
Number · percentage of participants
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815
percentage of participantsPart J: mRNA-1273.231 50 μgPart J: mRNA-1273.815 50 μg
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.81561.2 (46.2 to 74.8)69.4 (54.6 to 81.7)
PrimarySRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815

Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 29 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

Time frame:
Day 29
Reported as:
Number · percentage of participants
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815
percentage of participantsPart J: mRNA-1273.231 50 μgPart J: mRNA-1273.815 50 μg
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815100 (88.8 to 100.0)100 (90.5 to 100.0)
PrimarySRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815

Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 29 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

Time frame:
Day 29
Reported as:
Number · percentage of participants
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815
percentage of participantsPart J: mRNA-1273.231 50 μgPart J: mRNA-1273.815 50 μg
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.81561.2 (46.2 to 74.8)67.3 (52.5 to 80.1)
SecondaryGMT of Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273

GMT of serum pseudovirus nAb ID50 titers against ancestral SARS-CoV-2 (D614G) at Day 29 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Day 29
Reported as:
Geometric mean · titer
GMT of Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273
titerPart F (Cohort 2): mRNA-1273.529 50 μgPart F (Cohort 2): mRNA-1273 50 μg
GMT of Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-12734951.8 (4349.0 to 5638.0)5621.4 (5029.2 to 6283.4)
Statistical analysis
  • Part F (Cohort 2): mRNA-1273.529 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Gmr: 0.836 · 95% CI 0.745 to 0.938SARS-CoV-2 (D614G) nAb: Part F (Cohort 2): mRNA-1273.529 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
SecondarySRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273

Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) at Day 29 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Day 29
Reported as:
Number · percentage of participants
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273
percentage of participantsPart F (Cohort 2): mRNA-1273.529 50 μgPart F (Cohort 2): mRNA-1273 50 μg
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273100 (98.7 to 100)100 (98.6 to 100)
Statistical analysis
  • Part F (Cohort 2): mRNA-1273.529 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Srr difference: 0SARS-CoV-2 (D614G) nAb: Part F (Cohort 2): mRNA-1273.529 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg 95% CI could not be calculated due to the SRR difference is 0.
SecondarySRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273

Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) at Day 29 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Day 29
Reported as:
Number · percentage of participants
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273
percentage of participantsPart F (Cohort 2): mRNA-1273.529 50 μgPart F (Cohort 2): mRNA-1273 50 μg
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-127329.7 (24.3 to 35.5)43.0 (36.9 to 49.3)
Statistical analysis
  • Part F (Cohort 2): mRNA-1273.529 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Srr difference: -13.1 · 95% CI -21.2 to -5.0SARS-CoV-2 (D614G) nAb: Part F (Cohort 2): mRNA-1273.529 50 μg versus Part F (Cohort 2): mRNA-1273 50 μg
SecondarySRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) on Days 29, 91, 181, and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) on Days 29, 91, 181, and 366 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Days 29, 91, 181, and 366
Reported as:
Number · percentage of participants
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) on Days 29, 91, 181, and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
percentage of participantsPart G: mRNA-1273.214 50 μgPart F (Cohort 2): mRNA-1273 50 μg
Day 29100 (98.9 to 100.0)100 (98.6 to 100.0)
Day 91100 (98.9 to 100.0)99.6 (97.7 to 100.0)
Day 18199.4 (97.7 to 99.9)99.6 (97.7 to 100.0)
Day 36697.9 (94.8 to 99.4)99.4 (96.9 to 100.0)
Statistical analysis
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Srr difference: 0SARS-CoV-2 (D614G) nAb at Day 29: Part G versus Part F (Cohort 2) mRNA-1273 95% CI could not be calculated due to the SRR difference is 0.
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Srr difference: 0.9 · 97.5% CI -1.6 to 3.5SARS-CoV-2 (D614G) nAb at Day 91: Part G versus Part F (Cohort 2) mRNA-1273
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Srr difference: -0.1 · 95% CI -2.3 to 2.1SARS-CoV-2 (D614G) nAb at Day 181: Part G versus Part F (Cohort 2) mRNA-1273
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Srr difference: -1.9 · 95% CI -5.3 to 1.5SARS-CoV-2 (D614G) nAb at Day 366: Part G versus Part F (Cohort 2) mRNA-1273
SecondarySRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) on Days 29, 91, 181, and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) on Days 29, 91, 181, and 366 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Days 29, 91, 181, and 366
Reported as:
Number · percentage of participants
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) on Days 29, 91, 181, and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
percentage of participantsPart G: mRNA-1273.214 50 μgPart F (Cohort 2): mRNA-1273 50 μg
Day 2953.9 (48.4 to 59.3)43.0 (36.9 to 49.3)
Day 9127.4 (22.6 to 32.5)18.1 (13.5 to 23.5)
Day 18129.5 (24.5 to 35.0)19.2 (14.4 to 24.8)
Day 36632.6 (26.1 to 39.7)27.9 (21.5 to 35.1)
Statistical analysis
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Srr difference: 10.9 · 97.5% CI 1.7 to 20.1SARS-CoV-2 (D614G) nAb at Day 29: Part G versus Part F (Cohort 2) mRNA-1273
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Srr difference: 9.2 · 97.5% CI 1.4 to 17.0SARS-CoV-2 (D614G) nAb at Day 91: Part G versus Part F (Cohort 2) mRNA-1273
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Srr difference: 10.1 · 95% CI 3.0 to 17.2SARS-CoV-2 (D614G) nAb at Day 181: Part G versus Part F (Cohort 2) mRNA-1273
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Srr difference: 4.3 · 95% CI -5.0 to 13.6SARS-CoV-2 (D614G) nAb at Day 366: Part G versus Part F (Cohort 2) mRNA-1273
SecondaryGMT of Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 181 - mRNA-1273.222 (Part H)

GMT of serum pseudovirus nAb ID50 titers against BA.4/BA.5 at Day 181 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

Time frame:
Day 181
Reported as:
Geometric mean · titer
GMT of Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 181 - mRNA-1273.222 (Part H)
titerPart H: mRNA-1273.222 50 μg
GMT of Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 181 - mRNA-1273.222 (Part H)1424.7 (1123.5 to 1806.7)
SecondaryGMT of Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 181 - mRNA-1273.222 (Part H) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

GMT of serum pseudovirus nAb ID50 titers against ancestral SARS-CoV-2 (D614G) at Day 181 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Day 181
Reported as:
Geometric mean · titer
GMT of Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 181 - mRNA-1273.222 (Part H) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
titerPart H: mRNA-1273.222 50 μgPart F (Cohort 2): mRNA-1273 50 μg
GMT of Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 181 - mRNA-1273.222 (Part H) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)2906.6 (2465.4 to 3426.9)2393.3 (2047.4 to 2797.6)
Statistical analysis
  • Part H: mRNA-1273.222 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Gmr: 1.818 · 95% CI 1.469 to 2.249SARS-CoV-2 (D614G) nAb: Part H versus Part F (Cohort 2) mRNA-1273
SecondarySRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 181 - mRNA-1273.222 (Part H)

Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 181 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

Time frame:
Day 181
Reported as:
Number · percentage of participants
SRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 181 - mRNA-1273.222 (Part H)
percentage of participantsPart H: mRNA-1273.222 50 μg
SRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 181 - mRNA-1273.222 (Part H)89.9 (84.7 to 93.8)
SecondarySRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 181 - mRNA-1273.222 (Part H) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) at Day 181 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Day 181
Reported as:
Number · percentage of participants
SRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 181 - mRNA-1273.222 (Part H) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
percentage of participantsPart H: mRNA-1273.222 50 μgPart F (Cohort 2): mRNA-1273 50 μg
SRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 181 - mRNA-1273.222 (Part H) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)100 (98.1 to 100.0)99.6 (97.7 to 100.0)
Statistical analysis
  • Part H: mRNA-1273.222 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Srr difference: 0 · 95% CI -2.6 to 2.5SARS-CoV-2 (D614G) nAb: Part H versus Part F (Cohort 2) mRNA-1273
SecondarySRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 181 - mRNA-1273.222 (Part H)

Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 181 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.

Time frame:
Day 181
Reported as:
Number · percentage of participants
SRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 181 - mRNA-1273.222 (Part H)
percentage of participantsPart H: mRNA-1273.222 50 μg
SRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 181 - mRNA-1273.222 (Part H)77.2 (70.6 to 83.0)
SecondarySRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 181 - mRNA-1273.222 (Part H) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) at Day 181 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Day 181
Reported as:
Number · percentage of participants
SRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 181 - mRNA-1273.222 (Part H) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
percentage of participantsPart H: mRNA-1273.222 50 μgPart F (Cohort 2): mRNA-1273 50 μg
SRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 181 - mRNA-1273.222 (Part H) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)45.0 (37.7 to 52.4)19.2 (14.4 to 24.8)
Statistical analysis
  • Part H: mRNA-1273.222 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Srr difference: 25.5 · 95% CI 16.9 to 34.1SARS-CoV-2 (D614G) nAb: Part H versus Part F (Cohort 2) mRNA-1273
SecondarySRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Days 181 and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Days 181 and 366 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.

Time frame:
Days 181 and 366
Reported as:
Number · percentage of participants
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Days 181 and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
percentage of participantsPart G: mRNA-1273.214 50 μgPart F (Cohort 2): mRNA-1273 50 μg
Day 18194.5 (91.3 to 96.7)90.3 (85.8 to 93.7)
Day 36694.8 (90.6 to 97.5)89.8 (84.4 to 93.9)
Statistical analysis
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Srr difference: 5.0 · 95% CI 0.3 to 9.8Omicron BA.1 Variant (B.1.1.529) nAb at Day 181: Part G versus Part F (Cohort 2) mRNA-1273
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Srr difference: 5.6 · 95% CI -0.3 to 11.5Omicron BA.1 Variant (B.1.1.529) nAb at Day 366: Part G versus Part F (Cohort 2) mRNA-1273
SecondarySRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Days 181 and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Days 181 and 366 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.

Time frame:
Days 181 and 366
Reported as:
Number · percentage of participants
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Days 181 and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
percentage of participantsPart G: mRNA-1273.214 50 μgPart F (Cohort 2): mRNA-1273 50 μg
Day 18140.9 (35.4 to 46.6)25.9 (20.5 to 32.0)
Day 36652.8 (45.6 to 60.1)44.7 (37.3 to 52.3)
Statistical analysis
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Srr difference: 14.5 · 95% CI 6.7 to 22.3Omicron BA.1 Variant (B.1.1.529) nAb at Day 181: Part G versus Part F (Cohort 2) mRNA-1273
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Srr difference: 8.0 · 95% CI -2.1 to 18.0Omicron BA.1 Variant (B.1.1.529) nAb at Day 366: Part G versus Part F (Cohort 2) mRNA-1273
SecondaryGMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) and Ancestral SARS-CoV-2 (D614G) on Days 181 and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)

GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) on Days 181 and 366 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.

Time frame:
Days 181 and 366
Reported as:
Geometric mean · titer
GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) and Ancestral SARS-CoV-2 (D614G) on Days 181 and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
titerPart G: mRNA-1273.214 50 μgPart F (Cohort 2): mRNA-1273 50 μg
SARS-CoV-2 (B.1.1.529) nAb: Day 1811044.9 (853.5 to 1279.2)693.7 (550.7 to 873.9)
SARS-CoV-2 (D614G) nAb: Day 1812683.2 (2300.6 to 3129.5)2393.3 (2047.4 to 2797.6)
SARS-CoV-2 (B.1.1.529) nAb: Day 3661364.6 (1050.0 to 1773.6)1019.7 (776.3 to 1339.4)
SARS-CoV-2 (D614G) nAb: Day 3662679.5 (2157.6 to 3327.5)2492.3 (2032.3 to 3056.5)
Statistical analysis
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Gmr: 1.637 · 95% CI 1.243 to 2.155SARS-CoV-2 (B.1.1.529) nAb at Day 181: Part G versus Part F (Cohort 2) mRNA-1273
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Gmr: 1.373 · 95% CI 0.953 to 1.976SARS-CoV-2 (B.1.1.529) nAb at Day 366: Part G versus Part F (Cohort 2) mRNA-1273
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Gmr: 1.271 · 95% CI 1.051 to 1.537SARS-CoV-2 (D614G) nAb at Day 181: Part G versus Part F (Cohort 2) mRNA-1273
  • Part G: mRNA-1273.214 50 μg vs Part F (Cohort 2): mRNA-1273 50 μg · Gmr: 1.101 · 95% CI 0.830 to 1.461SARS-CoV-2 (D614G) nAb at Day 366: Part G versus Part F (Cohort 2) mRNA-1273

Adverse events

Collected over Day 1 up to the end of the study (Day 366 for Parts A.1, B, C, D, F, and G; Day 181 for Parts A.2, H, J). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A.1: mRNA-1273.211 50 µg1/300 (0.3%)6/300 (2%)133/300 (44.3%)
Part A.1: mRNA-1273.211 100 µg0/593 (0%)26/593 (4.4%)275/593 (46.4%)
Part A.2: mRNA-1273.214 50 µg0/135 (0%)3/135 (2.2%)38/135 (28.1%)
Part B: mRNA-1273 100 µg1/305 (0.3%)15/305 (4.9%)144/305 (47.2%)
Part C: mRNA-1273.617.2 50 µg0/581 (0%)27/581 (4.6%)288/581 (49.6%)
Part C: mRNA-1273.617.2 100 µg1/586 (0.2%)12/586 (2%)329/586 (56.1%)
Part D: mRNA-1273.213 50 µg0/327 (0%)8/327 (2.4%)188/327 (57.5%)
Part D: mRNA-1273.213 100 µg0/583 (0%)18/583 (3.1%)309/583 (53%)
Part E: mRNA-1273.213 100 µg0/42 (0%)0/42 (0%)34/42 (81%)
Part F (Cohort 1): mRNA-1273.529 50 µg0/133 (0%)2/133 (1.5%)57/133 (42.9%)
Part F (Cohort 2): mRNA-1273 50 µg2/376 (0.5%)20/376 (5.3%)193/376 (51.3%)
Part F (Cohort 2): mRNA-1273.529 50 µg0/375 (0%)16/375 (4.3%)188/375 (50.1%)
Part G: mRNA-1273.214 50 µg2/437 (0.5%)23/437 (5.3%)224/437 (51.3%)
Part H: mRNA-1273.222 50 µg2/510 (0.4%)12/510 (2.4%)178/510 (34.9%)
Part J: mRNA-1273.231 50 µg0/50 (0%)3/50 (6%)13/50 (26%)
Part J: mRNA-1273.815 50 µg0/50 (0%)2/50 (4%)11/50 (22%)
Most frequent serious events
Showing 10 of 191
Most frequent serious events
EventPart A.1: mRNA-1273.211 50 µgPart A.1: mRNA-1273.211 100 µgPart A.2: mRNA-1273.214 50 µgPart B: mRNA-1273 100 µgPart C: mRNA-1273.617.2 50 µgPart C: mRNA-1273.617.2 100 µgPart D: mRNA-1273.213 50 µgPart D: mRNA-1273.213 100 µgPart E: mRNA-1273.213 100 µgPart F (Cohort 1): mRNA-1273.529 50 µgPart F (Cohort 2): mRNA-1273 50 µgPart F (Cohort 2): mRNA-1273.529 50 µgPart G: mRNA-1273.214 50 µgPart H: mRNA-1273.222 50 µgPart J: mRNA-1273.231 50 µgPart J: mRNA-1273.815 50 µg
Colonic abscessInfections and infestations0/3000/5930/1350/3050/5810/5860/3270/5830/420/1330/3760/3750/4370/5101/500/50
DiverticulitisInfections and infestations0/3000/5930/1350/3050/5810/5860/3270/5830/420/1330/3760/3750/4370/5101/500/50
Pelvic inflammatory diseaseInfections and infestations0/3000/5930/1350/3050/5810/5860/3270/5830/420/1330/3760/3750/4370/5100/501/50
Tubo-ovarian abscessInfections and infestations0/3000/5930/1350/3050/5810/5860/3270/5830/420/1330/3760/3750/4370/5100/501/50
Ventricular tachycardiaCardiac disorders0/3000/5930/1350/3050/5810/5860/3270/5830/420/1330/3760/3750/4370/5100/501/50
NephrolithiasisRenal and urinary disorders0/3000/5930/1350/3050/5810/5860/3270/5830/420/1330/3760/3751/4371/5101/500/50
FallInjury, poisoning and procedural complications0/3000/5930/1350/3050/5810/5860/3270/5830/420/1330/3760/3751/4370/5101/500/50
OsteoarthritisMusculoskeletal and connective tissue disorders0/3004/5930/1350/3052/5810/5860/3270/5830/420/1333/3761/3751/4370/5100/500/50
Umbilical hernia, obstructiveGastrointestinal disorders0/3000/5930/1350/3050/5810/5860/3270/5830/421/1330/3760/3750/4370/5100/500/50
Non-cardiac chest painGeneral disorders0/3000/5930/1350/3050/5810/5860/3270/5830/421/1330/3761/3750/4370/5100/500/50
Most frequent other events
Most frequent other events
EventPart A.1: mRNA-1273.211 50 µgPart A.1: mRNA-1273.211 100 µgPart A.2: mRNA-1273.214 50 µgPart B: mRNA-1273 100 µgPart C: mRNA-1273.617.2 50 µgPart C: mRNA-1273.617.2 100 µgPart D: mRNA-1273.213 50 µgPart D: mRNA-1273.213 100 µgPart E: mRNA-1273.213 100 µgPart F (Cohort 1): mRNA-1273.529 50 µgPart F (Cohort 2): mRNA-1273 50 µgPart F (Cohort 2): mRNA-1273.529 50 µgPart G: mRNA-1273.214 50 µgPart H: mRNA-1273.222 50 µgPart J: mRNA-1273.231 50 µgPart J: mRNA-1273.815 50 µg
COVID-19Infections and infestations76/300143/59321/13587/305195/581227/586117/327220/58318/4230/133127/376119/375160/43774/5105/502/50
Upper respiratory tract infectionInfections and infestations27/30063/5936/13521/30549/58149/58638/32753/58315/429/13333/37631/37536/43736/5104/502/50
Asymptomatic COVID-19Infections and infestations14/30040/5937/13520/30528/58121/58633/32714/5835/4212/13321/37627/37518/43724/5100/500/50
Rhinovirus infectionInfections and infestations14/30019/5934/1359/30522/58136/58611/32725/5833/425/13318/37611/37527/43725/5103/505/50
NasopharyngitisInfections and infestations0/3001/5930/13516/3052/5818/5860/3274/5834/420/1332/3760/3750/4376/5100/500/50
Respiratory disorderRespiratory, thoracic and mediastinal disorders0/3000/5930/1351/3051/5811/5860/3270/5834/420/1330/3763/3753/4371/5100/500/50
HeadacheNervous system disorders6/30024/5933/1356/30527/58132/58610/32724/5831/4212/1339/37615/37511/43721/5102/501/50
FatigueGeneral disorders12/30036/5934/1356/30530/58129/58624/32733/5830/4211/13318/37617/37515/43725/5101/500/50
BronchitisInfections and infestations4/3006/5930/13516/3055/5817/5865/32724/5831/422/1337/3765/3758/4374/5101/500/50
HypertensionVascular disorders12/30020/5930/13510/30513/58120/58617/32711/5830/423/13318/37616/37513/4378/5101/501/50

Baseline characteristics

Safety Set included all participants who received IP. Total number of enrolled and treated participants in the study = 5161. All participants of Part A.2 rolled over from Part A.1 and some participants of Parts J rolled over from Part H. Hence, the baseline characteristics data of Part A.2 and Parts J are reported in a separate row.

Age, Categorical
Age, Categorical(Participants)Part A.1: mRNA-1273.211 50 μgPart A.1: mRNA-1273.211 100 μgPart A.2: mRNA-1273.214 50 μgPart B: mRNA-1273 100 μgPart C: mRNA-1273.617.2 50 μgPart C: mRNA-1273.617.2 100 μgPart D: mRNA-1273.213 50 μgPart D: mRNA-1273.213 100 μgPart E: mRNA-1273.213 100 μgPart F (Cohort 1): mRNA-1273.529 50 μgPart F (Cohort 2): mRNA-1273 50 μgPart F (Cohort 2): mRNA-1273.529 50 μgPart G: mRNA-1273.214 50 μgPart H: mRNA-1273.222 50 μgPart J: mRNA-1273.231 50 μgPart J: mRNA-1273.815 50 μgTotal
All Parts Excluding Part A.2 and Parts J — <=18 years00—00000000000——0
All Parts Excluding Part A.2 and Parts J — Between 18 and 65 years238447—21646646729242641115226254263405——3856
All Parts Excluding Part A.2 and Parts J — >=65 years62146—8911511935157118150121174105——1292
Part A.2 and Parts J — <=18 years——0———————————000
Part A.2 and Parts J — Between 18 and 65 years——112———————————4339194
Part A.2 and Parts J — >=65 years——23———————————71141
Sex: Female, Male
Sex: Female, Male(Participants)Part A.1: mRNA-1273.211 50 μgPart A.1: mRNA-1273.211 100 μgPart A.2: mRNA-1273.214 50 μgPart B: mRNA-1273 100 μgPart C: mRNA-1273.617.2 50 μgPart C: mRNA-1273.617.2 100 μgPart D: mRNA-1273.213 50 μgPart D: mRNA-1273.213 100 μgPart E: mRNA-1273.213 100 μgPart F (Cohort 1): mRNA-1273.529 50 μgPart F (Cohort 2): mRNA-1273 50 μgPart F (Cohort 2): mRNA-1273.529 50 μgPart G: mRNA-1273.214 50 μgPart H: mRNA-1273.222 50 μgPart J: mRNA-1273.231 50 μgPart J: mRNA-1273.815 50 μgTotal
All Parts Excluding Part A.2 and Parts J — Female167330—1313132872042842370190173258316——2746
All Parts Excluding Part A.2 and Parts J — Male133263—1742682991232991963186202179194——2402
Part A.2 and Parts J — Female——75———————————3130136
Part A.2 and Parts J — Male——60———————————192099
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A.1: mRNA-1273.211 50 μgPart A.1: mRNA-1273.211 100 μgPart A.2: mRNA-1273.214 50 μgPart B: mRNA-1273 100 μgPart C: mRNA-1273.617.2 50 μgPart C: mRNA-1273.617.2 100 μgPart D: mRNA-1273.213 50 μgPart D: mRNA-1273.213 100 μgPart E: mRNA-1273.213 100 μgPart F (Cohort 1): mRNA-1273.529 50 μgPart F (Cohort 2): mRNA-1273 50 μgPart F (Cohort 2): mRNA-1273.529 50 μgPart G: mRNA-1273.214 50 μgPart H: mRNA-1273.222 50 μgPart J: mRNA-1273.231 50 μgPart J: mRNA-1273.815 50 μgTotal
All Parts Excluding Part A.2 and Parts J — Hispanic or Latino3851—66100106326811737474658——667
All Parts Excluding Part A.2 and Parts J — Not Hispanic or Latino262538—23747547429451241113339324390447——4446
All Parts Excluding Part A.2 and Parts J — Unknown or Not Reported04—26613030415——35
Part A.2 and Parts J — Hispanic or Latino——15———————————6930
Part A.2 and Parts J — Not Hispanic or Latino——120———————————4340203
Part A.2 and Parts J — Unknown or Not Reported——0———————————112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A.1: mRNA-1273.211 50 μgPart A.1: mRNA-1273.211 100 μgPart A.2: mRNA-1273.214 50 μgPart B: mRNA-1273 100 μgPart C: mRNA-1273.617.2 50 μgPart C: mRNA-1273.617.2 100 μgPart D: mRNA-1273.213 50 μgPart D: mRNA-1273.213 100 μgPart E: mRNA-1273.213 100 μgPart F (Cohort 1): mRNA-1273.529 50 μgPart F (Cohort 2): mRNA-1273 50 μgPart F (Cohort 2): mRNA-1273.529 50 μgPart G: mRNA-1273.214 50 μgPart H: mRNA-1273.222 50 μgPart J: mRNA-1273.231 50 μgPart J: mRNA-1273.815 50 μgTotal
All Parts Excluding Part A.2 and Parts J — American Indian or Alaska Native15—05123001301——22
All Parts Excluding Part A.2 and Parts J — Asian918—6235110262616141411——206
All Parts Excluding Part A.2 and Parts J — Native Hawaiian or Other Pacific Islander01—00212001200——9
All Parts Excluding Part A.2 and Parts J — Black or African American1934—175432234912628213156——391
All Parts Excluding Part A.2 and Parts J — White257518—2794734812824783897322325381425——4356
All Parts Excluding Part A.2 and Parts J — More than one race77—1710612012778——75
All Parts Excluding Part A.2 and Parts J — Unknown or Not Reported710—2199313136349——89
Part A.2 and Parts J — American Indian or Alaska Native——1———————————001
Part A.2 and Parts J — Asian——1———————————214
Part A.2 and Parts J — Native Hawaiian or Other Pacific Islander——0———————————000
Part A.2 and Parts J — Black or African American——10———————————4418
Part A.2 and Parts J — White——117———————————4145203
Part A.2 and Parts J — More than one race——2———————————204
Part A.2 and Parts J — Unknown or Not Reported——4———————————105
09

Study locations

23 sites
  • Benchmark Research (California)
    Sacramento, California 95864, United States
  • Research Centers of America
    Hollywood, Florida 33024, United States
  • Jacksonville Center For Clinical Research
    Jacksonville, Florida 32216, United States
  • Meridian Clinical Research-(Savannah Georgia)
    Savannah, Georgia 31406, United States
  • Meridian Clinical Research (Iowa)
    Sioux City, Iowa 51106, United States
  • Johnson County Clinical Trials
    Lenexa, Kansas 66219, United States
  • Meridian Clinical Research-(Baton Rouge, Louisiana)
    Baton Rouge, Louisiana 70809, United States
  • Benchmark Research
    Metairie, Louisiana 70006, United States
  • Meridian Clinical Research-(Rockville Maryland)
    Rockville, Maryland 20854, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Washington State University
    Saint Louis, Missouri 63110, United States
  • Sundance Clinical Research
    Saint Louis, Missouri 63141, United States
  • Meridian Clinical Research (Grand Island, Nebraska)
    Grand Island, Nebraska 68803, United States
  • Meridian Clinical Research (Norfolk-Nebraska)
    Norfolk, Nebraska 68701, United States
  • Meridian Clinical Research-(Omaha Nebraska)
    Omaha, Nebraska 68134, United States
  • Meridian Clinical Research, LLC
    New York, New York 13901, United States
  • Trial Management Associates
    Wilmington, North Carolina 28403, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Benchmark Research - Austin - HyperCore
    Austin, Texas 78705, United States
  • Tekton Research, Inc.
    Austin, Texas 78745, United States
  • Benchmark Research - Fort Worth - HyperCore
    Fort Worth, Texas 76135, United States
  • Texas Center for Drug Development, Inc.
    Houston, Texas 77081, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
10

References and documents

Publications

  • Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, McGhee N, Tomassini JE, Chen X, Chang Y, Sutherland A, Montefiori DC, Girard B, Edwards DK, Feng J, Zhou H, Baden LR, Miller JM, Das R. A Bivalent Omicron-Containing Booster Vaccine against Covid-19. N Engl J Med. 2022 Oct 6;387(14):1279-1291. doi: 10.1056/NEJMoa2208343. Epub 2022 Sep 16. PubMed 36112399 ↗
  • Chalkias S, Schwartz H, Nestorova B, Feng J, Chang Y, Zhou H, Dutko FJ, Edwards DK, Montefiori D, Pajon R, Leav B, Miller JM, Das R. Safety and Immunogenicity of a 100 mug mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). medRxiv [Preprint]. 2022 Mar 7:2022.03.04.22271830. doi: 10.1101/2022.03.04.22271830. PubMed 35291289 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Nov 2023, 29 months.

Results were first posted in Feb 2025, 1 year 3 months after primary completion.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 29 months is above that.

Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2021
First posted
Jun 15, 2021
StartActual
May 28, 2021
Primary completionActual
Nov 17, 2023
CompletionActual
Nov 17, 2023
Results first posted
Feb 28, 2025
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04927065
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Jun 15, 2021
Start date
May 28, 2021
Primary completion
Nov 17, 2023
Completion
Nov 17, 2023
Results posted
Feb 28, 2025
Last update
Feb 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: 2019-nCoV Vaccine mRNA-1273 · mRNA-1273.214 COVID-19 vaccine · Elasomeran/Davesomeran

Start the discussion